Global and Chinese Monoclonal Antibody Industry ReportPR Newswire UK (press release)In 2012, the global best-selling Infliximab (Johnson & Johnson), Etanercept (Amgen), Bevacizumab (Roche), Rituximab (Roche), Adalimumab (AbbVie) and Trastuzumab (Ro…
|
Ensayo indica Rituximab alivia la ansiedad en pacientes con linfoma folicular
Terra Argentina En un ensayo clínico, la terapia de mantenimiento con rituximab redujo la ansiedad asociada con el cáncer frente a la espera vigilada en pacientes sin síntomas con linfoma folicular “no voluminoso” avanzado. El fármaco también difirió la necesidad de … |
|
Ensayo indica Rituximab alivia la ansiedad en pacientes con linfoma folicular
Terra Perú En un ensayo clínico, la terapia de mantenimiento con rituximab redujo la ansiedad asociada con el cáncer frente a la espera vigilada en pacientes sin síntomas con linfoma folicular “no voluminoso” avanzado. El fármaco también difirió la necesidad de … |
OncLiveObinutuzumab Gains Role in CLL GuidelinesOncLiveThe first-in-class glycoengineered type-2 antibody has demonstrated superior outcomes in combination with chlorambucil to both a rituximab (Rituxan) plus chlorambucil regimen and to chlorambucil al…
|
Concise analysis of China’s rituximab drug market
News-Medical.net Research and Markets (http://www.researchandmarkets.com/research/7dhkqb/investigation) has announced the addition of the “Investigation Report on China Rituximab Market, 2009-2018″ report to their offering. Rituximab (trade names “”MabThera”” by … Investigation Report on China Rituximab Market, 2009-2018PR Newswire (press release) |
OncLiveGilead Sciences Moves Ahead on Idelalisib FilingsOncLiveCombination treatment with idelalisib and rituximab (Rituxan) was associated with a >70% improvement in overall survival (OS) in patients with high-risk relapsed/refractory CLL, accordin…
|
BUSINESS | PRESS RELEASES
The Providence Journal Clinical data and the opinions of interviewed thought leaders indicate that Lemtrada, Biogen Idec/AbbVie’s daclizumab, and Roche/Genentech’s ocrelizumab offer improvements in ARR over first-line injectable mainstays (e.g., Teva’s Copaxone). Surveyed … |
|
Greater Effect on Disability Remains the Top Opportunity in Relapsing …
PR Newswire (press release) Clinical data and the opinions of interviewed thought leaders indicate that Lemtrada, Biogen Idec/AbbVie’s daclizumab, and Roche/Genentech’s ocrelizumab offer improvements in ARR over first-line injectable mainstays (e.g., Teva’s Copaxone). Surveyed … |
|
Clinical Trial Finds Zolinza Effective for B-cell Non-Hodgkin’s Lymphoma …
PR Web (press release) Although certain B-cell Non-Hodgkin’s Lymphomas, such as follicular lymphoma, may initially respond well to rituximab-based chemotherapy, the cancer often returns. This tendency to relapse is why follicular lymphoma is considered incurable. In the … |
|
Clinical Trial Finds Zolinza Effective for B-cell Non-Hodgkin’s Lymphoma …
Virtual-Strategy Magazine (press release) Although certain B-cell Non-Hodgkin’s Lymphomas, such as follicular lymphoma, may initially respond well to rituximab-based chemotherapy, the cancer often returns. This tendency to relapse is why follicular lymphoma is considered incurable. In the … |